Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Abhijit Parolia"'
Autor:
Jae Eun Choi, Yuanyuan Qiao, Ilona Kryczek, Jiali Yu, Jonathan Gurkan, Yi Bao, Mahnoor Gondal, Jean Ching-Yi Tien, Tomasz Maj, Sahr Yazdani, Abhijit Parolia, Houjun Xia, JiaJia Zhou, Shuang Wei, Sara Grove, Linda Vatan, Heng Lin, Gaopeng Li, Yang Zheng, Yuping Zhang, Xuhong Cao, Fengyun Su, Rui Wang, Tongchen He, Marcin Cieslik, Michael D. Green, Weiping Zou, Arul M. Chinnaiyan
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-15 (2024)
Abstract Cancer treatment continues to shift from utilizing traditional therapies to targeted ones, such as protein kinase inhibitors and immunotherapy. Mobilizing dendritic cells (DC) and other myeloid cells with antigen presenting and cancer cell k
Externí odkaz:
https://doaj.org/article/110a46dd843f458b99af5d4a3c335b08
Autor:
Michael B. Mumphrey, Noshad Hosseini, Abhijit Parolia, Jie Geng, Weiping Zou, Malini Raghavan, Arul Chinnaiyan, Marcin Cieslik
Publikováno v:
Cell Reports, Vol 42, Iss 8, Pp 112965- (2023)
Summary: Disruption of antigen presentation via loss of major histocompatibility complex (MHC) expression is a strategy whereby cancer cells escape immune surveillance and develop resistance to immunotherapy. Here, we develop the personalized genomic
Externí odkaz:
https://doaj.org/article/d0c6d870f1f846c894747d75024f6dd8
Autor:
Rebecca L. Mather, Abhijit Parolia, Sandra E. Carson, Erik Venalainen, David Roig‐Carles, Mustapha Jaber, Shih‐Chun Chu, Ilaria Alborelli, Rebecca Wu, Dong Lin, Noushin Nabavi, Elena Jachetti, Mario P. Colombo, Hui Xue, Perla Pucci, Xinpei Ci, Cheryl Hawkes, Yinglei Li, Hardev Pandha, Igor Ulitsky, Crystal Marconett, Luca Quagliata, Wei Jiang, Ignacio Romero, Yuzhuo Wang, Francesco Crea
Publikováno v:
Molecular Oncology, Vol 15, Iss 7, Pp 1921-1941 (2021)
Metastatic neuroendocrine prostate cancer (NEPC) is a highly aggressive disease, whose incidence is rising. Long noncoding RNAs (lncRNAs) represent a large family of disease‐ and tissue‐specific transcripts, most of which are still functionally u
Externí odkaz:
https://doaj.org/article/f7cf993958bb411fa6d76321470eff17
Autor:
Abhijit Parolia, Erik Venalainen, Hui Xue, Rebecca Mather, Dong Lin, Rebecca Wu, Perla Pucci, Jason Rogalski, Joseph R. Evans, Felix Feng, Colin C. Collins, Yuzhuo Wang, Francesco Crea
Publikováno v:
Molecular Oncology, Vol 13, Iss 5, Pp 1121-1136 (2019)
Prostate cancer (PCa) is driven by the androgen receptor (AR)‐signaling axis. Hormonal therapy often mitigates PCa progression, but a notable number of cases progress to castration‐resistant PCa (CRPC). CRPC retains AR activity and is incurable.
Externí odkaz:
https://doaj.org/article/4f4d44b860634a0cb28586f9a1c33e31
Autor:
Noushin Nabavi, Nur Ridzwan Nur Saidy, Erik Venalainen, Anne Haegert, Abhijit Parolia, Hui Xue, Yuwei Wang, Rebecca Wu, Xin Dong, Colin Collins, Francesco Crea, Yuzhuo Wang
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-10 (2017)
Abstract Carcinoma of the prostate is the most common cancer in men. Treatment of aggressive prostate cancer involves a regiment of radical prostectomy, radiation therapy, chemotherapy and hormonal therapy. Despite significant improvements in the las
Externí odkaz:
https://doaj.org/article/30400add8b0940e997d768e861520881
Autor:
Mateus Mota, Stefan R. Sweha, Matt Pun, Siva Kumar Natarajan, Yujie Ding, Chan Chung, Debra Hawes, Fusheng Yang, Alexander R. Judkins, Susanta Samajdar, Xuhong Cao, Lanbo Xiao, Abhijit Parolia, Arul M. Chinnaiyan, Sriram Venneti
Publikováno v:
Proceedings of the National Academy of Sciences. 120
Diffuse midline gliomas (DMGs) including diffuse intrinsic pontine gliomas (DIPGs) bearing lysine-to-methionine mutations in histone H3 at lysine 27 (H3K27M) are lethal childhood brain cancers. These tumors harbor a global reduction in the transcript
Autor:
Arul M. Chinnaiyan, A. Robert MacLeod, Youngsoo Kim, Ajjai S. Alva, Xuhong Cao, Alice Xu, Kristin M. Juckette, Andrew Delekta, Esther Luo, Xiaojun Jing, Fengyun Su, Heng Zheng, Xiaoju Wang, Sudhanshu Shukla, Yuanyuan Qiao, Lisha Wang, Yajia Zhang, Abhijit Parolia, Mengyao Tan, Josh Vo, Jean C. Tien, Lanbo Xiao
Supplementary Table 1: List of the compounds in the epigenetic inhibitor library.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0056b26f4599a31c81525a93542a9cb
https://doi.org/10.1158/0008-5472.22419987.v1
https://doi.org/10.1158/0008-5472.22419987.v1
Autor:
Arul M. Chinnaiyan, A. Robert MacLeod, Youngsoo Kim, Ajjai S. Alva, Xuhong Cao, Alice Xu, Kristin M. Juckette, Andrew Delekta, Esther Luo, Xiaojun Jing, Fengyun Su, Heng Zheng, Xiaoju Wang, Sudhanshu Shukla, Yuanyuan Qiao, Lisha Wang, Yajia Zhang, Abhijit Parolia, Mengyao Tan, Josh Vo, Jean C. Tien, Lanbo Xiao
This file includes Supplementary Figures S1-S8. Figure S1: Inhibition of EPZ6438 and ASO-EZH2 sensitizes enzalutamide-resistant LNCaP cells to enzalutamide or ASO-AR. Figure S2: Design and validation of sgRNA targeting EZH2. Figure S3: Growth inhibit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b74e293913dbca7b62487c878666eba
https://doi.org/10.1158/0008-5472.22419990.v1
https://doi.org/10.1158/0008-5472.22419990.v1
Autor:
Arul M. Chinnaiyan, A. Robert MacLeod, Youngsoo Kim, Ajjai S. Alva, Xuhong Cao, Alice Xu, Kristin M. Juckette, Andrew Delekta, Esther Luo, Xiaojun Jing, Fengyun Su, Heng Zheng, Xiaoju Wang, Sudhanshu Shukla, Yuanyuan Qiao, Lisha Wang, Yajia Zhang, Abhijit Parolia, Mengyao Tan, Josh Vo, Jean C. Tien, Lanbo Xiao
Supplementary information with additional materials and methods, references, and the legends for all supplementary figures.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ae87a07609a8acae31b96f5c8d4555b
https://doi.org/10.1158/0008-5472.22419996.v1
https://doi.org/10.1158/0008-5472.22419996.v1
Autor:
Arul M. Chinnaiyan, A. Robert MacLeod, Youngsoo Kim, Ajjai S. Alva, Xuhong Cao, Alice Xu, Kristin M. Juckette, Andrew Delekta, Esther Luo, Xiaojun Jing, Fengyun Su, Heng Zheng, Xiaoju Wang, Sudhanshu Shukla, Yuanyuan Qiao, Lisha Wang, Yajia Zhang, Abhijit Parolia, Mengyao Tan, Josh Vo, Jean C. Tien, Lanbo Xiao
Advanced prostate cancer initially responds to androgen deprivation therapy (ADT), but the disease inevitably recurs as castration-resistant prostate cancer (CRPC). Although CRPC initially responds to abiraterone and enzalutamide, the disease invaria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9f2c3a2f68aa78b18e9a1b8942680041
https://doi.org/10.1158/0008-5472.c.6510525.v1
https://doi.org/10.1158/0008-5472.c.6510525.v1